We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors reduce the risks for adverse kidney and ...

Higher baseline serum magnesium levels are linked to a higher risk for cardiac events in HFmrEF/HFpEF, while empagliflozin treatment shows a lower risk for these events in those with higher magnesium.

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...

SGLT2 inhibitors reduce the risk for adverse kidney outcomes across most high-risk populations with CKD, heart failure, and/or type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (SGLT2i) ...

In older adults with cardiovascular disease, SGLT2 inhibitors significantly reduced the risk for the composite outcome of hospitalization or urgent visits for heart failure and cardiovascular death.

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...

Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable risks of hospitalization for ...

Two classes of diabetes drugs may also improve cardiovascular and kidney disease outcomes in people with or without diabetes. In a meta-analysis involving more than 70,000 patients with diabetes, ...

After a 6-day court trial, the Federal Trade Commission successfully blocked Edwards Lifesciences from buying JenaValve over ...

Regardless of duration of type 2 diabetes, sodium-glucose cotransporter inhibitors prevented cardiovascular events, according to research presented at the European Society of Cardiology Congress 2024.

HOUSTON -- SGLT2 inhibitors may hold a benefit for a wider pool of patients with chronic kidney disease (CKD) than previously thought, a pair of meta-analyses indicated. SGLT2 inhibitors helped to ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors cut the risk for adverse CV outcomes ...